CFO
REGN icon

CVA Family Office’s Regeneron Pharmaceuticals REGN Stock Holding History

CVA Family Office’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.2K Sell
143
-51
-26% -$34.7K 0.01% 496
2026
Q1 		$150K Buy
194
+49
+34% +$37.5K 0.02% 374
2025
Q4 		$112K Sell
145
-5
-3% -$3.4K 0.01% 398
2025
Q3 		$84.3K Buy
150
+10
+7% +$5.65K 0.01% 450
2025
Q2 		$73.5K Sell
140
-25
-15% -$14K 0.01% 468
2025
Q1 		$105K Buy
165
+11
+7% +$7.57K 0.02% 383
2024
Q4 		$110K Buy
154
+9
+6% +$7.55K 0.02% 374
2024
Q3 		$152K Buy
145
+6
+4% +$6.68K 0.02% 301
2024
Q2 		$146K Buy
139
+1
+0.7% +$969 0.03% 292
2024
Q1 		$133K Buy
138
+1
+0.7% +$951 0.02% 312
2023
Q4 		$120K Buy
+137
New +$113K 0.02% 308
2023
Q3 		– Sell
-123
Closed -$88.4K – 785
2023
Q2 		$88.4K Hold
123
– – 0.02% 327
2023
Q1 		$101K Buy
123
+3
+3% +$2.26K 0.02% 309
2022
Q4 		$86.6K Buy
120
+5
+4% +$3.69K 0.02% 305
2022
Q3 		$79K Buy
115
+20
+21% +$12.6K 0.02% 277
2022
Q2 		$56K Sell
95
-50
-34% -$32.5K 0.02% 344
2022
Q1 		$101K Buy
145
+50
+53% +$31.6K 0.02% 255
2021
Q4 		$60K Buy
+95
New +$58.4K 0.01% 330
2021
Q3 		– Sell
-95
Closed -$53K – 769
2021
Q2 		$53K Buy
95
+25
+36% +$12.7K 0.02% 357
2021
Q1 		$33K Buy
+70
New +$34.1K 0.01% 325

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

CVA Family Office's REGN Position: Q2 2026 in Review

CVA Family Office reduced its Regeneron Pharmaceuticals (REGN) stake by 26% in Q2 2026, selling an estimated $34.7K and leaving 143 shares worth $89.2K. The position accounts for 0.01% of the portfolio, ranked #496.

CVA Family Office first reported a position in REGN in Q1 2021 and has held it in 20 quarters since. The position peaked at $152K in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • CVA Family Office held 143 shares of Regeneron Pharmaceuticals worth $89.2K as of Q2 2026.
  • CVA Family Office sold 51 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $34.7K.
  • Regeneron Pharmaceuticals made up 0.01% of CVA Family Office's portfolio in Q2 2026, its #496 holding.
  • CVA Family Office first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 20 quarters since.
  • CVA Family Office's Regeneron Pharmaceuticals position peaked at $152K in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.